High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers

Journal of Urology

Volumn 163, Issue 2, 2000, Pages 623-629

  Halmos, Gabor ^b   Arencibia, José M ^b   Schally, Andrew V ^a   Davis, Rodney ^b   Bostwick, David G ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Gleason score; Human prostate cancer; Luteinizing hormone releasing hormone receptors; Receptor messenger ribonucleic acid

Indexed keywords

CETRORELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; IODINE 125; MESSENGER RNA; TRIPTORELIN;

ARTICLE; BINDING AFFINITY; CANCER HORMONE THERAPY; DISSOCIATION CONSTANT; GENE EXPRESSION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN TISSUE; MALE; MALE GENITAL TRACT CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033963203     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67947-5     Document Type: Article

References (35)

1. Landis, S. H., Murray, T., Bolden, S. and Wingo, P. A.: Cancer statistics. CA Cancer J Clin, 48: 6, 1998
2. Schroeder, F. H. and Boyle, P.: Screening of prostate cancer -necessity or nonsense? Eur J Cancer, 29A: 656, 1993
3. Huggins, C. and Hodges, C. V.: Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res, 1: 293, 1941
4. Sogani, P. C. and Fair, W. R.: Treatment of advanced prostatic cancer. Urol Clin North Am, 14: 353, 1987
5. Schally, A. V. and Comaru-Schally, A. M.: Hypothalamic and other peptide hormones. In: Cancer Medicine. 4th ed. Edited by Holland, J. F., Frei III, E., Bast Jr., R. C., Kufe, D. E., Morton, D. L. and Weichselbaum, R. R. Baltimore: Williams and Wilkins vol. 1, chapter 71, pp. 1067-1086, 1997
6. Schally, A. V. and Comaru-Schally, A. M.: Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions. Adv Drug Deliv Rev, 28: 157, 1997
7. Tolis, G., Ackman, D., Stellos, A., Mehta, A., Labrie, F., Fazekas, A. T., Comaru-Schally, A. M. and Schally, A. V.: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA, 79: 1658, 1982
8. Bruchovsky, N., Goldenberg, S. L., Akakura, K. and Rennie, P. S.: Luteinizing hormone-releasing hormone agonists in prostate cancer. Cancer, 72: 1685, 1993
9. Sharifi, R., Soloway, M. and the Leuprolide Study Group: Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol, 143: 68, 1990
10. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A. and Goodman, P. J.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med, 321: 419, 1989
11. Parmar, H., Lightman, S. L., Allen, L., Phillips, R. H., Edwards, L. and Schally, A. V.: Randomised controlled study of orchidectomy vs. long-acting D-Trp-6-LH-RH microcapsules in advanced prostatic carcinoma. Lancet, 2: 1202, 1985
12. Gonzalez-Barcena, D., Vadillo-Buenfil, M., Gomez-Orta, F., Fuentes Garcia, M., Cardenas-Cornejo, I., Graef-Sanchez, A., Comaru-Schally, A. M. and Schally, A. V.: Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate, 24: 84, 1994
13. Gonzalez-Barcena, D., Vadillo-Buenfil, M., Cortez-Morales, A., Fuentes-Garcia, M., Cardenas-Cornejo, I., Comaru-Schally, A. M. and Schally, A. V.: Luteinizing hormone-releasing hormone antagonist Cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology, 45: 275, 1995
14. Emons, G., Ortmann, O., Schulz, K-D. and Schally, A. V.: Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol Metab, 8: 355, 1997
15. Fekete, M., Redding, T. W., Comaru-Schally, A. M., Pontes, J. D., Connelly, R. W., Srkalovic, G. and Schally, A. V.: Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate, 14: 191, 1989
16. Qayum, A., Gullick, W., Clayton, R. C., Sikora, K. and Waxman, J.: The effect of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer, 62: 96, 1990
17. Limonta, P., Dondi, D., Moretti, R. M., Maggi, R. and Motta, M.: Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab, 75: 207, 1992
18. Dondi, D., Limonta, P., Moretti, R. M., Marelli, M. M., Garattini, E. and Motta, M.: Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res, 54: 4091, 1994
19. Srkalovic, G., Bokser, L., Radulovic, S., Korkut, E. and Schally, A. V.: Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R-3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75. Endocrinology, 127: 3052, 1990
20. Pinski, J., Reile, H., Halmos, G., Groot, K. and Schally, A. V.: Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Int J Cancer, 59: 51, 1994
21. Halmos, G., Wittliff, J. L. and Schally, A. V.: Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res, 55: 280, 1995
22. Bradford, M. M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72: 248, 1976
23. Halmos, G., Schally, A. V., Pinski, J., Vadillo-Buenfil, M. and Groot, K.: Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LHRH) in rats by LHRH antagonist Cetrorelix. Proc Natl Acad Sci USA, 93: 2398, 1996
24. Kakar, S., Musgrove, L. C., Devor, D. C., Sellers, J. C. and Neill, J. D.: Cloning, sequencing and expression of human gonadotropin releasing hormone (GnRH) receptor. Biochem Biophys Res Commun, 189: 289, 1992
25. Munson, P. J. and Rodbard, D. A.: A versatile computerized approach for characterization of ligand binding systems. Anal Biochem, 107: 220, 1980
26. Scatchard, B.: The attraction of proteins for small molecules and ions. Ann NY Acad Sci, 51: 660, 1949
27. Comaru-Schally, A. M., Brannan, W., Schally, A. V., Colcolough, M. and Monga, M.: Efficacy and safety of luteinizing hormone-releasing hormone antagonist Cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab, 83: 3826, 1998
28. Koppan, M., Nagy, A., Schally, A. V., Plonowski, A., Halmos, G., Arencibia, J. M. and Groot, K.: Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate, 38: 151, 1999
29. Lamharzi, N., Halmos, G., Jungwirth, A. and Schally, A. V.: Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist Cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int J Oncol, 13: 429, 1998
30. Nagy, A., Schally, A. V., Armatis, P., Szepeshazi, K., Halmos, G., Kovacs, M., Zarandi, M., Groot, K., Miyazaki, M., Jungwirth, A. and Horvath, J.: Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA, 93: 7269, 1996
31. Halmos, G., Nagy, A., Lamharzi, N. and Schally, A. V.: Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high-affinity to human breast cancers. Cancer Lett, 136: 129, 1999
32. Miyazaki, M., Nagy, A., Schally, A. V., Lamharzi, N., Halmos, G., Szepeshazi, K., Groot, K. and Armatis, P.: Growth inhibition of human ovarian cancers by cytotoxic analogs of luteinizing hormone-releasing hormone. J Natl Cancer Inst, 89: 1803, 1997
33. Jungwirth, A., Schally, A. V., Nagy, A., Pinski, J., Groot, K., Galvan, G., Szepeshazi, K. and Halmos, G.: Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analogs of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int J Oncol, 10: 877, 1997
34. Miyazaki, M., Schally, A. V., Nagy, A., Lamharzi, N., Halmos, G., Szepeshazi, K. and Armatis, P.: Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. Am J Obstet Gynecol, 180: 1095, 1999
35. Murphy, W. M.: Prognostic factors in the pathological assessment of prostate cancer. Hum Pathol, 29: 427, 1998